EXAS Similar Chart Price Prediction
The price of EXAS is predicted to go up -2.48%, based on the high correlation periods with MRIN. The similarity of these two price pattern on the periods is 91.77%.
EXAS
MRIN
Down: -2.48%Similarity: 91.77%
EXAS Revenue Forecast
EXAS EPS Forecast
EXAS FAQs
What is bull’s view on EXAS?
What is bear's view on EXAS?
What is EXAS revenue forecast for next quarter？
What is EXAS eps forecast for next quarter？
EXAS VS S&P500
Cologuard's staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard's market share could soar past 10%.
Exact is positioned for growth regardless of how liquid biopsies play out, and the firm's liquid biopsy initiative is a good hedge in case Cologuard feels competitive pressure.
Exact has a robust pipeline of liquid biopsy offerings, including minimal residual disease (MRD), multicancer early detection (MCED), and CRC screening.
EXAS Analyst's Forecast
Luke Sergott
Barclays
Buy
2025-01-23
Price Target
$70
Upside
+26.97%
Barclays initiated coverage of Exact Sciences with an Overweight rating and $70 price target. The firm started the liquid biopsy space with Overweight ratings on three names. The technology is "breaking out" with broader adoption across key markets, the analyst tells investors in a research note. Barclays expects volumes to continue to ramp as companies publish data, expand menus across indications and markets, and payers increase coverage across lives as this technology continues to show its utility. "It is too early to pick a winner given how early we are in adoption, so in the meantime we believe that a rising tide will lift all boats," contends the firm. Barclays sees a "very long runway" from the underpenetrated markets as coverage unlocks selling prices and additional indications unlock more addressable markets.
Derik De Bruin
B of A Securities
Strong Buy
2024-12-13
Price Target
$75 → $72
Upside
+17.55%
Dan Brennan
TD Cowen
Strong Buy
2024-11-26
Price Target
$82 → $86
Upside
+43.09%
